Latest News - Oklahoma Society of Clinical Oncology

U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma August 25, 2026 Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front-line GEA Company to host […]

Bristol Myers Squibb (NYSE: BMY) today announced that Opdivo® (nivolumab) has received approval for two new classical Hodgkin Lymphoma (cHL) indications in the U.S. and the European Union (EU). The U.S. Food and Drug Administration (FDA) granted approval of Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and pediatric patients 12 years and older […]

Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program PRINCETON, N.J.–(BUSINESS WIRE)– Bristol Myers Squibb (NYSE: BMY) today announced positive interim Phase 3 results from the SUCCESSOR-2 study (NCT05552976). In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated […]

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved a new treatment regimen for CALQUENCE® (acalabrutinib) in combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Approval was based on results from the randomized, multicenter, open-label phase III AMPLIFY trial. AMPLIFY 3.5-Year Data […]

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer’s broader landmark Most […]

“Bridging the Tribal Inequity Gap to Early Lung Cancer Screening” is an initiative aimed at increasing lung cancer screening rates in American Indian and Alaska Native (AI/AN) communities through a culturally tailored toolkit. Designed for both healthcare providers and community members, the toolkit raises awareness, shares best practices, and supports improved screening rates in historically underserved populations. This resource directly addresses systemic barriers—including access, trust, and cultural responsiveness—while equipping clinics and communities with practical, relevant educational resources. For your reference, here is a […]

AstraZeneca announced that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, is now FDA-approved as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer as determined by an FDA-approved test. ENHERTU has Boxed WARNINGS for interstitial lung disease (ILD)/pneumonitis and embryo-fetal toxicity.

US approval of AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for the treatment of adult patients with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. The approved regimen includes neoadjuvant IMFINZI in combination with chemotherapy before surgery, followed by adjuvant IMFINZI in […]

“Bridging the Tribal Inequity Gap to Early Lung Cancer Screening” is an initiative aimed at increasing lung cancer screening rates in American Indian and Alaska Native (AI/AN) communities through a culturally tailored toolkit. Designed for both healthcare providers and community members, the toolkit raises awareness, shares best practices, and supports improved screening rates in historically underserved populations. This resource directly addresses systemic barriers—including access, trust, and cultural responsiveness—while equipping clinics and communities with practical, relevant educational resources. For your reference, here is a […]

To learn more about the latest data from TAGRISSO, visit the website here. Please see full Prescribing Information, including Patient Information for TAGRISSO. TAGRISSO is a registered trademark of the AstraZeneca group of companies. ©2025 AstraZeneca.    All rights reserved.    US-105694   Last Updated 10/25